COVID-19 IMPACT SURVEY MAY 2020
The global market for Cardiac Ablation is projected to reach US$1.4 billion by 2025, driven by the growing burden of cardiovascular diseases worldwide. Apart from circulatory disorders caused by high blood pressure and coronary artery disease such as blockages in arteries, electrical disorders, also known as conduction disorders of the heart are also a major class of cardiovascular disease. Arrhythmias/abnormal/irregular heart rhythms can sometimes be fatal when not treated properly. Electrical impulses travel through the heart to control the heartbeat. When disruptions in the electrical flow occur it results in irregular heartbeat and rhythm. In a normal heart, electrical impulses travel down the right and left branches of the ventricles at the same speed allowing both the ventricles to contract simultaneously. When a block is encountered in the one of the ventricles, the electrical signal is rerouted through a different path result in the one ventricle contracting slower that the other resulting in arrhythmia. Arrhythmias such as Tachycardia and Bradycardia are often treated with medications, such as beta blockers and/or through surgical implantation of cardioverter defibrillator (ICD) or pacemaker.
However, in patients unresponsive to medications and/or intolerant to its side-effects, cardiac ablation remains the standard of care for treating electrical disorders of the heart. Cardiac ablation is aimed at destroying malfunctioning tissues responsible for triggering abnormal heart rhythms. Cardiac ablation significantly improves the chances of survival of patients with atrial fibrillation. Types of arrhythmias often treated with cardiac ablation include atrial flutter ablation, pulmonary vein isolation, SVT ablation, and ventricular tachycardia ablation. Catheter ablation and surgical ablation are the two popular types of cardiac ablation techniques. Types of catheter ablation include radiofrequency ablation and cryoablation both of which includes the use of catheters to either send radiofrequency energy to scar the defective tissue or deliver extreme cold to freeze and destroy the tissue. Benefits of catheter ablation include less invasive; reduces risk of sudden cardiac arrest by over 60%; and faster recovery. Surgical ablation includes Maze and Mini maze procedures, both of which are invasive procedures. The market in the coming years is poised to immensely benefit from ongoing R&D in the use of robotic ablation of atrial fibrillation. Companies are developing robotic catheter systems that will enable more stable and precise steerability of the catheter. Robotic surgical ablation systems bring numerous benefits such as smaller incisions, eliminates catheter-tissue contact issues, higher catheter stability when compared to manual manipulation, reduced fluoroscopy exposure, ability to remotely steer the catheter, and reduction in operator error. Few of the remote navigation technologies being developed include magnetic field vectors and electromechanical. The United States and Europe represent large markets worldwide with a combined share of 74.2% of the market. China ranks as the fastest growing market with a CAGR of 16.1% over the analysis period supported by the country's rapidly developing cardiovascular care system. Economic prosperity, globalization of unhealthy lifestyles, and rise in chronic diseases like hypertension, obesity, and diabetes mellitus have all pushed up the risk for cardiovascular disease (CVD) in the country. The Chinese government's recent approval of the "Healthy China 2030 Plan" aims to reduce morbidity and mortality from CVDs by developing its healthcare systems and providing funding support for science and technology innovation.